CA-SYNACK
6.6.2019 17:02:17 CEST | Business Wire | Press release
Today, Synack, the most trusted crowdsourced security testing platform and top choice of major enterprises and governments, becomes the only crowdsourced penetration testing company to offer secure and managed workspaces with endpoint control. LaunchPoint+ extends Synack’s original LaunchPoint VPN offering by providing a managed workspace environment for crowdsourced testing of enterprise and government assets.
In the midst of calls for greater consumer privacy from the European Commission to Apple, and states like NY and CA introducing bold privacy bills, Synack is launching their new LaunchPoint+ product to help organizations meet today’s rising security standards. Just as Apple now provides privacy-as-a-service (PaaS) to accommodate consumer privacy demands in their latest iOS upgrade, Synack is providing additional privacy and data control to its customers.
As GDPR, HIPAA, PCI-DSS and ISO 27001 require increasingly stringent requirements for data privacy, Synack has developed a new offering to help meet, and in some cases exceed, what is required. In use cases that require extra care (such as where PII data is involved), consumers and regulators alike are increasingly demanding more attention for data privacy. A violation of GDPR could result in a fine of up to 4% of annual revenue, incentivizing organizations to protect the data in their care.
Many organizations, both governments and enterprises, are held to regulatory standards that demand heightened requirements around privacy. For others such as Apple, enforcement of privacy is a way to develop more trust with their customers and differentiate their brands. In a recent survey by SAS, 73% of consumers said their concerns over data privacy were increasing. Synack has responded by providing managed workspaces with endpoint controls to give these organizations the data protection and privacy environment during the testing period that they need.
As the leader of crowdsourced security, Synack has continuously brought to market new technology features that build, measure, and demonstrate trust between enterprises and their customers, and organizations and ethical hackers. Through innovations like the Attacker Resistance Score, Coverage Analytics, Trust Report, and Guardians of Trust Awards, Synack has put the trust and privacy of its customers first. LaunchPoint+ is another example of that commitment.
For Synack customers, the company’s new workspace will enable endpoint control, data privacy objectives, and improved trust between customers and researchers.
“We’ve set out to build trust between organizations and ethical hackers since our founding in 2013. We’re really excited to continue enhancing the Synack platform with technology feature updates like LaunchPoint+, because these are what give customers more control and make the crowdsourced testing model more trusted,” Synack CTO and co-founder Mark Kuhr said.
“The ability to have enhanced security controls directly applied to the attack workstation will help ensure data privacy and compliance requirements are met and consistently enforced,” says David Charlton, former Head of Penetration Testing at J.P. Morgan Chase & Co, and Synack’s Head of Product Strategy.
For Synack Red Team researchers, LaunchPoint+ will eradicate the need to manually connect to a VPN server and ensure a stable connection with reduced network latency. When asked for feedback, Synack Red Team researchers said they were “happy with the concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot.”
As more security teams move towards crowdsourced penetration testing, Synack leads the way in trust by offering features like LaunchPoint+ that ensure private, safe and controlled testing.
About Synack
Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005487/en/
Contact:
Ellie McCardwell press@synack.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
